Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's Full Year and Q4 2024 results. [Operator Instructions].

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS) ...

Cash Increase (Full Year 2024): $9.9 million post-Natroba acquisition. Cipher Pharmaceuticals Inc (CPHRF) reported a significant increase in total net revenue for Q4 2024, reaching $11.8 million, a ...